Please assess the completion status of the following clinical trial:

Trial Title: The Single, Multiple Dose and Food Effect Study of SHR2285 Tablets on Pharmacokinetics and Pharmacodynamics in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy subjects, aged 18-55 (including boundary);~2. Body mass index (BMI) between 18 to 28 kg/m2 (including boundary), male body weight ≥50 kg and \<90 kg , female body weight ≥45kg and \<90kg;~3. Participant with no clinically significant findings in vital signs, physical examination, 12-lead ECG ,X-ray and laboratory parameters.~4. Understand the study procedures and methods, voluntary to participate in the study and signed the informed consent.~Exclusion Criteria:~1. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) or total bilirubin/direct bilirubin \> upper limit of normal (ULN) during screening/baseline.~2. Serum creatinine\> ULN during screening/baseline.~3. Positive faecal occult blood~4. Abnormal coagulation function.~5. A clinical history of coagulation dysfunction; subjects with adverse reaction of antiplatelet drugs or anticoagulant drugs.~6. Subjects with severe head trauma or head surgery within 2 years or surgery within 3 months prior to the screening.~7. Blood donation or blood loss within 1 month≥200 mLor≥400 mL within 3 months before administration.~8. Human immunodeficiency virus antibody, syphilis serological examination, hepatitis b virus surface antigen, hepatitis c virus antibody were positive.~9.3 months prior to screening involved in any drug or medical device clinical studies or within 5 half-life of drugs before screening.~10.Female subjects who did not receive contraception at least 30 days before administration and etc.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- SHR2285 Part 1A (Type: EXPERIMENTAL): Participant received one of 7 dose levels of SHR2285 tablet as single-dose oral administration
- Placebo Part 1A (Type: PLACEBO_COMPARATOR): Single ascending doses of placebo orally
- SHR2285 Part 1B (Type: EXPERIMENTAL): Participant received one dose of SHR2285 tablet as single-dose oral administration
- Placebo Part 1B (Type: PLACEBO_COMPARATOR): Single doses of placebo orally
- SHR2285 Part 2 (Type: EXPERIMENTAL): Participant received one of 4 dose levels of SHR2285 tablet as multi-dose oral administration
- Placebo Part 2 (Type: PLACEBO_COMPARATOR): Multiple ascending doses of placebo orally

Based on this trial design, predict the completion outcome and termination type (if applicable).